We hypothesized that translation inhibition in AR-low prostate cancer might be lethal or confer a competitive disadvantage to AR low epithelial cells, and that the bulk of the remaining epithelia did not express the 4ebp1M and were simply castrate cells that did not express the transgene. This evidence concerns the gene AR and prostate cancer.